术前栓塞可改善非典型WHO 2级脑膜瘤的局部控制并调节基因表达。

IF 13.4 1区 医学 Q1 CLINICAL NEUROLOGY
Alexander F Haddad, Rithvik Ramesh, Naomi Zakimi, Jia-Shu Chen, Daniel Quintana, Eugene Gil, Aymen S Kabir, Youssef E Sibih, Blanca Morales Lugo, Shubhang Bhalla, William C Chen, Javier E Villanueva-Meyer, Kazim H Narsinh, Stephen T Magill, Ramin A Morshed, Ethan Winkler, Philip V Theodosopoulos, Michael W McDermott, Manish K Aghi, David R Raleigh
{"title":"术前栓塞可改善非典型WHO 2级脑膜瘤的局部控制并调节基因表达。","authors":"Alexander F Haddad, Rithvik Ramesh, Naomi Zakimi, Jia-Shu Chen, Daniel Quintana, Eugene Gil, Aymen S Kabir, Youssef E Sibih, Blanca Morales Lugo, Shubhang Bhalla, William C Chen, Javier E Villanueva-Meyer, Kazim H Narsinh, Stephen T Magill, Ramin A Morshed, Ethan Winkler, Philip V Theodosopoulos, Michael W McDermott, Manish K Aghi, David R Raleigh","doi":"10.1093/neuonc/noaf203","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Preoperative embolization is hypothesized to reduce blood loss and operative time for meningioma resection, but the impact of preoperative embolization on long-term oncological outcomes and molecular features of meningiomas is incompletely understood. Here we investigate how preoperative embolization influences perioperative and long-term outcomes and molecular features of atypical WHO grade 2 meningiomas.</p><p><strong>Methods: </strong>Patients who underwent resection of WHO grade 2 meningiomas from 1997 to 2021 were retrospectively identified from an institutional database. Univariate and multivariate Cox proportional hazards modeling and propensity matching were used for clinical analyses. Available DNA methylation profiling, bulk RNA sequencing, and targeted gene expression profiling data were used to elucidate how preoperative embolization influences the molecular architecture of atypical WHO grade 2 meningiomas.</p><p><strong>Results: </strong>A total of 319 patients with atypical WHO grade 2 meningiomas were identified, of which 106 (33.2%) underwent preoperative embolization without significant changes in perioperative outcomes, such as blood loss or operative time, in comparison to patients who did not undergo preoperative embolization. In propensity matched multivariate analyses, preoperative embolization was independently associated with longer recurrence free survival (RFS, HR 0.55, 95% CI 0.31-0.96, p=0.037), particularly in patients with subtotal resection (median RFS 16.2 years versus 5.9 years, p=0.045; HR 0.32, 95% CI 0.14-0.70, p=0.005). Bioinformatic analyses demonstrated that preoperative embolization led to enrichment of pathways linked to cellular differentiation and hypoxia, and suppression of pathways implicated in mitosis and cell cycle progression, suggesting that improved long-term oncological outcomes may occur through inhibition of the cell cycle in atypical WHO grade 2 meningiomas.</p><p><strong>Conclusions: </strong>Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningiomas, a subgroup of meningiomas that have intermediate clinical outcomes with standard interventions.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":13.4000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.\",\"authors\":\"Alexander F Haddad, Rithvik Ramesh, Naomi Zakimi, Jia-Shu Chen, Daniel Quintana, Eugene Gil, Aymen S Kabir, Youssef E Sibih, Blanca Morales Lugo, Shubhang Bhalla, William C Chen, Javier E Villanueva-Meyer, Kazim H Narsinh, Stephen T Magill, Ramin A Morshed, Ethan Winkler, Philip V Theodosopoulos, Michael W McDermott, Manish K Aghi, David R Raleigh\",\"doi\":\"10.1093/neuonc/noaf203\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Preoperative embolization is hypothesized to reduce blood loss and operative time for meningioma resection, but the impact of preoperative embolization on long-term oncological outcomes and molecular features of meningiomas is incompletely understood. Here we investigate how preoperative embolization influences perioperative and long-term outcomes and molecular features of atypical WHO grade 2 meningiomas.</p><p><strong>Methods: </strong>Patients who underwent resection of WHO grade 2 meningiomas from 1997 to 2021 were retrospectively identified from an institutional database. Univariate and multivariate Cox proportional hazards modeling and propensity matching were used for clinical analyses. Available DNA methylation profiling, bulk RNA sequencing, and targeted gene expression profiling data were used to elucidate how preoperative embolization influences the molecular architecture of atypical WHO grade 2 meningiomas.</p><p><strong>Results: </strong>A total of 319 patients with atypical WHO grade 2 meningiomas were identified, of which 106 (33.2%) underwent preoperative embolization without significant changes in perioperative outcomes, such as blood loss or operative time, in comparison to patients who did not undergo preoperative embolization. In propensity matched multivariate analyses, preoperative embolization was independently associated with longer recurrence free survival (RFS, HR 0.55, 95% CI 0.31-0.96, p=0.037), particularly in patients with subtotal resection (median RFS 16.2 years versus 5.9 years, p=0.045; HR 0.32, 95% CI 0.14-0.70, p=0.005). Bioinformatic analyses demonstrated that preoperative embolization led to enrichment of pathways linked to cellular differentiation and hypoxia, and suppression of pathways implicated in mitosis and cell cycle progression, suggesting that improved long-term oncological outcomes may occur through inhibition of the cell cycle in atypical WHO grade 2 meningiomas.</p><p><strong>Conclusions: </strong>Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningiomas, a subgroup of meningiomas that have intermediate clinical outcomes with standard interventions.</p>\",\"PeriodicalId\":19377,\"journal\":{\"name\":\"Neuro-oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":13.4000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/neuonc/noaf203\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noaf203","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:假设术前栓塞可以减少脑膜瘤切除术的出血量和手术时间,但术前栓塞对脑膜瘤的长期肿瘤预后和分子特征的影响尚不完全清楚。在这里,我们研究术前栓塞如何影响围手术期和长期预后以及非典型WHO 2级脑膜瘤的分子特征。方法:从一个机构数据库中回顾性地确定1997年至2021年接受who 2级脑膜瘤切除术的患者。临床分析采用单因素和多因素Cox比例风险模型和倾向匹配。可用的DNA甲基化谱、大量RNA测序和靶向基因表达谱数据用于阐明术前栓塞如何影响非典型WHO 2级脑膜瘤的分子结构。结果:共鉴定出319例非典型WHO 2级脑膜瘤患者,其中106例(33.2%)接受术前栓塞治疗,与未接受术前栓塞治疗的患者相比,围手术期预后(如出血量或手术时间)无明显变化。在倾向匹配的多变量分析中,术前栓塞与更长的无复发生存期独立相关(RFS, HR 0.55, 95% CI 0.31-0.96, p=0.037),特别是次全切除术患者(中位RFS 16.2年对5.9年,p=0.045; HR 0.32, 95% CI 0.14-0.70, p=0.005)。生物信息学分析表明,术前栓塞导致与细胞分化和缺氧相关的通路富集,并抑制与有丝分裂和细胞周期进展相关的通路,这表明非典型WHO 2级脑膜瘤可能通过抑制细胞周期来改善长期肿瘤预后。结论:术前栓塞改善了非典型WHO 2级脑膜瘤的局部控制并调节了基因表达,2级脑膜瘤是一种临床结果中等的脑膜瘤亚组。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.

Background: Preoperative embolization is hypothesized to reduce blood loss and operative time for meningioma resection, but the impact of preoperative embolization on long-term oncological outcomes and molecular features of meningiomas is incompletely understood. Here we investigate how preoperative embolization influences perioperative and long-term outcomes and molecular features of atypical WHO grade 2 meningiomas.

Methods: Patients who underwent resection of WHO grade 2 meningiomas from 1997 to 2021 were retrospectively identified from an institutional database. Univariate and multivariate Cox proportional hazards modeling and propensity matching were used for clinical analyses. Available DNA methylation profiling, bulk RNA sequencing, and targeted gene expression profiling data were used to elucidate how preoperative embolization influences the molecular architecture of atypical WHO grade 2 meningiomas.

Results: A total of 319 patients with atypical WHO grade 2 meningiomas were identified, of which 106 (33.2%) underwent preoperative embolization without significant changes in perioperative outcomes, such as blood loss or operative time, in comparison to patients who did not undergo preoperative embolization. In propensity matched multivariate analyses, preoperative embolization was independently associated with longer recurrence free survival (RFS, HR 0.55, 95% CI 0.31-0.96, p=0.037), particularly in patients with subtotal resection (median RFS 16.2 years versus 5.9 years, p=0.045; HR 0.32, 95% CI 0.14-0.70, p=0.005). Bioinformatic analyses demonstrated that preoperative embolization led to enrichment of pathways linked to cellular differentiation and hypoxia, and suppression of pathways implicated in mitosis and cell cycle progression, suggesting that improved long-term oncological outcomes may occur through inhibition of the cell cycle in atypical WHO grade 2 meningiomas.

Conclusions: Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningiomas, a subgroup of meningiomas that have intermediate clinical outcomes with standard interventions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuro-oncology
Neuro-oncology 医学-临床神经学
CiteScore
27.20
自引率
6.30%
发文量
1434
审稿时长
3-8 weeks
期刊介绍: Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信